You are here
FDA Approves Midodrine Hydrochloride Tablets
September 12, 2003
PITTSBURGH--(BUSINESS WIRE)--Sept. 11, 2003--Mylan Laboratories Inc. (NYSE:MYL - News) announced today that the U.S. Food and Drug Administration has granted final approval for its Abbreviated New Drug Application for Midodrine Hydrochloride Tablets in 2.5 mg, 5 mg and 10 mg strengths. Midodrine Hydrochloride is the generic version of Shire Pharmaceuticals ProAmatine®.
Mylan will be launching Midodrine Hydrochloride Tablets immediately.
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs